Authorized purpose: aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.
Clinical role
PET/CT visualization, segmentation, quantification, quality control, and structured reporting support.
Images and patients
PET/SPECT/Nuclear Medicine · Prostate
Key limitation
Keep in mind: Both aPROMISE and the predicate aBSI rely on the user to make the final selection of regions of interest that are considered as lesions. To create a report the signing user is required to confirm quality control, and electronically sign the report preview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Prostate Input: PSMA PET/CT image data in the form of DICOM files.
Who uses it?Intended users: Healthcare professionals and researchers.
What does the software produce?Output: The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.
What is its most important limitation?Key limitation: Both aPROMISE and the predicate aBSI rely on the user to make the final selection of regions of interest that are considered as lesions. To create a report the signing user is required to confirm quality control, and electronically sign the report preview.
Clinical takeaway. Clinical role: aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.
Evidence takeaway. Evidence from the reviewed source record: K211655 reports phantom validation, predicate comparison, analytical performance, and a clinical study comparing platform-supported PSMA PET/CT quantification with clinician assessment. The FDA summary does not provide one universal sensitivity or specificity value; exact tracer, acquisition, and version applicability must be checked before using candidate publications as performance evidence.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
aPROMISE is a cloud-based platform for healthcare professionals and researchers to accept, transfer, store, display, manipulate, quantify, and report PSMA PET/CT examinations using the PROMISE framework.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.
Exact FDA submission
Checked 2026-09-19
The exact packet supports PET/CT visualization, hotspot analysis, quantitative analysis, and signed-report export; it does not state the current disease-burden wording.
Both aPROMISE and the predicate aBSI rely on the user to make the final selection of regions of interest that are considered as lesions. To create a report the signing user is required to confirm quality control, and electronically sign the report preview.
Exact FDA submission
Checked 2026-09-19
These are the packet's direct user-confirmation and report-quality-control boundaries; tracer, acquisition, reconstruction, and literature limitations are not stated in this packet.
K211655 reports phantom validation, predicate comparison, analytical performance, and a clinical study comparing platform-supported PSMA PET/CT quantification with clinician assessment. The FDA summary does not provide one universal sensitivity or specificity value; exact tracer, acquisition, and version applicability must be checked before using candidate publications as performance evidence.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K211655 reports phantom validation, predicate comparison, analytical performance, and a clinical study comparing platform-supported PSMA PET/CT quantification with clinician assessment. The FDA summary does not provide one universal sensitivity or specificity value; exact tracer, acquisition, and version applicability must be checked before using candidate publications as performance evidence.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K211655 FDA performance package for aPROMISE
DesignManufacturer phantom, analytical, predicate-comparison, and clinical performance validation
PopulationPSMA PET/CT examinations for prostate-cancer imaging, quantification, and structured reporting
Scopeexact submission
Tested versionaPROMISE
IndependenceSponsor or vendor study
K211655
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
4 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211655 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: PSMA PET/CT image data in the form of DICOM files.
Scope: Exact FDA submission. The direct packet input statement replaces the current radiopharmaceutical-metadata addition.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.
Scope: Product family. Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Cloud-based web platform as described in K211655; confirm hosting region, tenant isolation, identity, retention, and current product build with the vendor.
Scope: Product family. Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.
Scope: Exact FDA submission. The exact packet supports PET/CT visualization, hotspot analysis, quantitative analysis, and signed-report export; it does not state the current disease-burden wording.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: The review page displays studies in a 4-panel view showing PET, CT, PET/CT fusion and maximum intensity projection (MIP) simultaneously. Selected or drawn hotspots are subject to automatic quantitative analysis. Signed reports are saved in the device and can be exported as a JPG or DICOM file.
Scope: Exact FDA submission. The exact packet supports PET/CT visualization, hotspot analysis, quantitative analysis, and signed-report export; it does not state the current disease-burden wording.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Cloud-based web platform as described in K211655; confirm hosting region, tenant isolation, identity, retention, and current product build with the vendor.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.
K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.
EXINI Diagnostics AB publishes a coordinated vulnerability disclosure policy covering EXINI products: vulnerability intake at support@exini.com, safe harbor for good-faith security researchers, coordinated disclosure timing, and investigation and patch handling commitments.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The policy covers EXINI products generally and does not name aPROMISE or any specific release; exact-release scope is not established.
Only qualified nuclear medicine physicians, radiologists, and trained imaging analysts should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K211655; confirm the exact cleared version, enabled options, deployment, and local compatibility.
K211655 describes DICOM transfer, a four-panel PET/CT/fusion/MIP display, ROI quantification, user quality control, electronic report confirmation, and archival workflow. Current EXINI or PYlarify material is product-family context and does not prove the exact deployed cloud configuration.
product family · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Quantification depends on tracer, acquisition, reconstruction, segmentation, image quality, and user quality-control steps; candidate literature and current family materials do not establish exact-version performance unless explicitly linked to the submission.
product family · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The packet identifies NM imaging using PSMA PET/CT and does not establish the current SPECT expansion. Controlled directory display reconciled from exact FDA wording: Nuclear medicine (NM) imaging using PSMA PET/CT. -> PET/SPECT/Nuclear Medicine.
The packet directly refers to body scans; it does not state prostate anatomy in the reviewed indication or summary. Controlled directory display reconciled from exact FDA wording: Body scans of PSMA PET/CT image data. -> Prostate.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
9Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: The Xeleris V Processing and Review System displays, processes, archives, prints, reports, and networks planar, SPECT, and PET nuclear-medicine data, with optional applications for DaTQUANT, lung analysis, brain analysis, coronary-flow reserve, prostate-cancer bone metastases, liver shunt and dose calculations, and monitoring of patient radiation doses from nuclear-medicine imaging data.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, lung, brain, liver, cardiac, coronary, and other anatomy represented in labeled nuclear-medicine studies
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.